Altre lingue Evelo Biosciences, Inc.

Azioni

EVLO

US2997342025

Mercato chiuso - OTC Markets Altri mercati azionari 15:30:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
0,0495 ^USD	+18,14%		+16,47%	-19,51%

2023	Evelo Biosciences, Inc. annuncia che Simba Gill cessa di essere l'Amministratore delegato	CI
2023	Evelo Biosciences, Inc. annuncia cambiamenti nell'esecutivo, con effetto dal 1° dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

North American Morning Briefing : More Tech -2-	25/04
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04
North American Morning Briefing : Focus Turns to -2-	04/04
North American Morning Briefing : Stocks Set for -2-	28/03
North American Morning Briefing : Investors -2-	21/03
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	14/12
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	11/12
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	11/12
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	21/11
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	21/11
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	21/11
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Sector Update: Health Care Stocks Retreat in Late Afternoon	17/10/23
Sector Update: Health Care	17/10/23
Top Midday Decliners	17/10/23
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	17/10/23
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	17/10/23
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17/10/23
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	17/10/23
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	10/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Evelo Biosciences, Inc.

Azioni

EVLO

US2997342025

Altre lingue

Filtri